Edwards Lifesciences Corporation
Analysis
Four reports, one story: Edwards keeps raising its outlook because TAVR re-accelerated on new evidence and mitral and tricuspid therapies are becoming a second growth engine. The catch is that the spending to create that demand lands before the patients do. How much of that patient-access spending is a permanent cost?
- The growth engine is no longer just TAVR.
Mitral and tricuspid sales grew roughly 45% while TAVR held near 10%, with three more launches due in the fourth quarter. Management points that portfolio at $2 billion by 2030, so growth no longer depends on any one product. Which of the fourth-quarter launches matters most to the $2 billion target?
- The TAVR rebound is better patient flow, not the new label.
Management says asymptomatic patients barely show up in claims data because Medicare does not yet cover the indication; the lift is doctors treating severe, symptomatic patients sooner. The biggest piece of the growth story stays unspent.
- Spending is landing before the sales it is meant to create.
Fourth-quarter running costs jumped by over $100 million on patient-access programs and field hires, and earnings missed. The JenaValve deal falling through keeps those costs off this year, so the margin gain looks better than it is. How does the margin path compare with Edwards' last big launch cycle?
- Referral behaviour keeps shifting toward earlier treatment. TAVR is still about three-quarters of sales, so if doctors keep sending patients sooner, most of the company grows.
- The Medicare policy due in September covers asymptomatic patients. It unlocks the approval Edwards already has but cannot bill for, turning it into paying procedures from 2027.
- Every fourth-quarter TMTT launch lands on schedule. Each new therapy treats patients the others cannot, so the second growth engine arrives before the first one slows.
- The lift from a competitor leaving Europe is now over. With that help gone and a harder second half ahead, growth has to come from real new patients, not a rival's exit.
- The Medicare policy comes back narrower than the draft. Tight care-team rules keep hospital capacity where it is, and the patients Edwards is counting on go untreated.
- Patient-access spending does not convert into more procedures. Spending on salespeople and marketing stays on the books while procedures never catch up, so the margin gain stalls.
| Politician | Transaction | Amount | Traded | Filed |
|---|---|---|---|---|
Donald Trump Republican · Executive | Purchase | ≥$50K | May 11 | Jul 1 |
Donald Trump Republican · Executive | Purchase | ≥$15K | Mar 11 | May 13 |
Donald Trump Republican · Executive | Purchase | ≥$15K | Mar 2 | May 13 |
Donald Trump Republican · Executive | Purchase | ≥$500K | Feb 10 | May 13 |
Ro Khanna Democratic · House · CA-17 | Sale | ≥$1K | Aug 3 | Sep 4 |
Congressional trading data provided by QuiverQuant
How Edwards Lifesciences turned $6.1B of revenue into $1.3B of operating income.
| Revenue | ||
|---|---|---|
| Transcatheter Heart Valves | $4.5B | ▲ 9.29% YoY |
| Surgical Heart Valve Therapy | $1.0B | ▲ 4.89% YoY |
| Transcatheter Mitral And Tricuspid Therapies | $550.6M | ▲ 56.38% YoY |
| Total revenue | $6.1B | |
| Gross profit | $4.7B | 78.0% |
| Operating income | $1.3B | 20.8% |